Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PRT-12396 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on PRT12396, a putative JAK2 V617F inhibitor (Apr 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PRT-12396 | PRT 12396|PRT12396 | JAK2 Inhibitor 20 | Limited information is currently available on PRT12396, a putative JAK2 V617F inhibitor (Apr 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07469891 | Phase I | PRT-12396 | A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms | Recruiting | USA | 0 |